Rating Change
Chardan Capital analysts downgraded Tenax Therapeutics, Inc. (NASDAQ:TENX) from Buy to Neutral on August 11, 2026.
downgradeNASDAQ:TENX
Tenax Therapeutics, Inc. (TENX) Downgraded to Neutral by Chardan Capital
Chardan Capital analysts downgraded Tenax Therapeutics, Inc. (NASDAQ:TENX) from Buy to Neutral on August 11, 2026.
At publication ·
What changed
Tenax Therapeutics, Inc. (NASDAQ:TENX) · downgrade
- Firm
- Chardan Capital
- Rating
- Buy to Neutral
- Price at event
- $1.62
- Market capitalization
- $45.0M
At a glance
Key takeaways
- Chardan Capital downgraded Tenax Therapeutics (TENX) from Buy to Neutral on August 11, 2026, which may prompt institutional investors to adjust positions.
Market Context
Tenax Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $1.62 with a market capitalization of $45.0M.
Analyst downgrades can weigh on a stock in the short term as institutional investors who follow Chardan Capital's research adjust their positions. However, downgrades also sometimes create buying opportunities if the market overreacts to the rating change. The reasoning behind the downgrade matters more than the rating itself.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Tenax Therapeutics, Inc.
Among the 10 most recent ratings: 7 Buy, 3 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 11, 2026 | Canaccord Genuity | Buy | N/A |
| Aug 11, 2026 | Chardan Capital | Neutral | N/A |
| Aug 11, 2026 | Guggenheim | Buy | N/A |
| Aug 11, 2026 | Evercore ISI Group | In-Line | N/A |
| Aug 10, 2026 | William Blair | Market Perform | N/A |
Related Tools: Analyst Ratings Dashboard | View TENX Stock Page
Frequently Asked Questions
What does the Neutral rating mean for TENX?
A rating of Neutral from Chardan Capital reflects the analyst's outlook on Tenax Therapeutics, Inc. (NASDAQ:TENX). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the TENX forecast page.